Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL

Guido Lancman; Amir Steinberg; Janice Gabrilove

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL

Int J Hematol Oncol Stem Cell Res. 2018 Jan 1;12(1):1-3.

Authors

Guido Lancman¹, Amir Steinberg², Janice Gabrilove²

Affiliations

¹ Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Tisch Cancer Institute, Mount Sinai Hospital, New York, NY, USA.

PMID: 29951170
PMCID: PMC6018244

Abstract

Serpentine supravenous hyperpigmentation (SSH) is a rare vasculo-cutaneous entity that has been associated with peripheral infusion of chemotherapy agents, in particular 5-FU¹^-³, but also seen with docetaxel⁴^,⁵, fotemustine⁶, and vinorelbine⁷. It consists of a marked hyperpigmentation along the superficial network of veins proximal to the chemotherapy infusion site and was originally described in a 1976 case report in association with 5-FU¹. Here, for the first time, we report SSH in association with R-CHOP chemotherapy.

Keywords: Chemotherapy; DLBCL; R- CHOP; SSH; Serpentine supravenous hyperpigmentation.

Publication types

Case Reports